Avalyn Pharma

Avalyn Pharma

Biotechnology, 2251 San Diego Ave Ste B111, Seattle, Washington, 92110, United States, 11-50 Employees

avalynpharma.com

  • LinkedIn

phone no Phone Number: 61********

Who is AVALYN PHARMA

Avalyn is a clinical-stage biopharmaceutical company developing inhaled therapies to treat rare respiratory diseases, including idiopathic pulmonary fibrosis and other interstitial lung d...

Read More

map
  • 2251 San Diego Ave Ste B111, Seattle, Washington, 92110, United States Headquarters: 2251 San Diego Ave Ste B111, Seattle, Washington, 92110, United States
  • 2011 Date Founded: 2011
  • 11-50 Employees: 11-50
  • dollar-icon Revenue: $1 Million to $5 Million
  • tech-icon Active Tech Stack: See technologies

industries-icon Industry: Biotechnology

SIC SIC Code: 2834 | NAICS Code: 325412 | Show More

checked-icon Does something look wrong? Fix it. | View contact records from AVALYN PHARMA

Avalyn Pharma Org Chart and Mapping

Employees

Deepthi Nair

Associate Director, Clinical Data Management

Alyssa Black

Senior Human Resources Manager

signout-image
You are signed out

Sign in to CIENCE GO Data to uncover contact details

crown-icon Free credits every month

Frequently Asked Questions Regarding Avalyn Pharma

Answer: Avalyn Pharma's headquarters are located at 2251 San Diego Ave Ste B111, Seattle, Washington, 92110, United States

Answer: Avalyn Pharma's phone number is 61********

Answer: Avalyn Pharma's official website is https://avalynpharma.com

Answer: Avalyn Pharma's revenue is $1 Million to $5 Million

Answer: Avalyn Pharma's SIC: 2834

Answer: Avalyn Pharma's NAICS: 325412

Answer: Avalyn Pharma has 11-50 employees

Answer: Avalyn Pharma is in Biotechnology

Answer: Avalyn Pharma contact info: Phone number: 61******** Website: https://avalynpharma.com

Answer: Avalyn is a clinical-stage biopharmaceutical company developing inhaled therapies to treat rare respiratory diseases, including idiopathic pulmonary fibrosis and other interstitial lung diseases. Our lead candidate, AP01, is a Phase 2b-ready inhaled formulation of pirfenidone in development for the treatment of pulmonary fibrosis

Answer:

Premium Sales Data for Prospecting

  • Sales data across over 200M records

  • Up-to-date records (less decayed data)

  • Accurate Email Lists (real-world tested)

  • Powerful search engine and intuitive interface

lock icon Get Full Access